Similarly, both ustekinumab, an anti-IL-12 and anti-IL-23 antibody (113), and the anti-IL-17 antibody secukinumab, were found to be effective for treating refractory mucocutaneous BD lesions (114). Here, IL17A is linked to Behcet disease.